|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia显示文摘 | O'Hare T Eide CA Deininger MW | 2007 | Blood2007，110，7： | 1 |
| 2 | New Bcr-Abl inhibitors in chronic myeloid leukemia:keeping resistance in check 显示文摘 | O'Hare T Eide CA Deininger MW | 2008 | Expert Opin Investig Drugs2008，17，6： | 1 |
| 3 | Targeting the BCR- ABL signaling pathway in therapy- resistant Philadelphia chromosome-positive leukemia显示文摘 | O'HARE T DEININGER MW EIDE CA | 2011 | Clin Cancer Res2011，17，2： | 1 |
| 4 | New Bcr-Abl inhibitors in chronic myeloid leukemia : keeping resistance in check 显示文摘 | O'Hare T Eide CA Deininger MW | 2008 | Expert Opin lnvestig Drugs2008，17，6： | 1 |
| 5 | Bcr-Abl kinase domain mutations,drug resistance,and the road to a cure for chronic myeloid leukemia显示文摘 | 0'Hare T Eide CA Deininger MWN | | 0，，07： | 1 |
| 6 | Chronic myeloid leukemia: advances inunderstanding disease biology and mechanisms of resistance totyrosine kinase inhibitors 显示文摘 | Eide CA 0丨Hare T | 2015 | Curr Hematol Malig Rep2015，10，2： | 1 |
| 7 | Dissociation,hardiness,and performance in military cadets participating in survival training显示文摘 | Eid J Morgan CA | 2006 | Mil Med2006，171，5： | 1 |
| 8 | Altitude illness:update on prevention and treatment显示文摘 | Eide RP 3rd Asplund CA | | 0，，03： | 1 |
| 9 | Bcr-Abl kinase domain mutations drug resistance,and the road to a cure for chronic myeloid leukemia显示文摘 | O'Hare T Eide CA Deininger MW | 2007 | Blood2007，110，7： | 1 |
| 10 | Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMNI07) in an N--ethyl-N-nitrosourea(ENU)-based mu- tagenesis-screen:high efficacy of drug combinations显示文摘 | Bradeen HA Eide CA O'Hare T | 2006 | Blood2006，108，7： | 1 |
| 11 | BCR-ABL 1 com- pound mutatios combining key kinase domain positions confer clinical resistance to Ponatinib in Ph chromosome-positive leu- kemia显示文摘 | Zabriskie MS Eide CA Tantravahi SK | 2014 | Cancer Cell2014，26，9： | 1 |
| 12 | New Bcr-Abl inhibitors in chronic myeloid leukemia:keeping resistance in check 显示文摘 | O'Hare T Eide CA Deininger MW | 2008 | Expert Opin Investig Drugs2008，17，6： | 1 |
| 13 | Chronic myeloid leukemia:advances in understanding disease bio logy and mechanisms of resistance to tyrosine kinase inhibitors显示文摘 | Eide CA O'Hare T | 2015 | Curr Hematol Malig Rep2015，10，： | 1 |
| 14 | Foretinib is a potent inhibitor of oncogenic ROS 1 fusion proteins显示文摘 | Davare MA Saborowski A Eide CA | 2013 | Proc Natl Acad Sci U S A2013，110，19： | 1 |
| 15 | Dissociation , hardiness , and perfor- mance in military cadets participating in survival training 显示文摘 | Eid J Morgan CA 3rd | 2006 | Military Medicine2006，171，5： | 1 |
| 16 | Altitude illness: update on prevention and treatment显示文摘 | Eide RP 3rd Asplund CA | 2012 | Curr Sports Med Rep2012，11，3： | 1 |
| 17 | Foretinib is a potent in- hibitor of oncogenic ROS1 fusion proteins显示文摘 | Davare MA Saborowski A Eide CA | 2013 | Proe Natl Acad Sci USA2013，110，19： | 1 |
| 18 | Persistent LYNsignaling in imatinib - resistant, BCR - ABL - independentchronicmyelogenous leukemia显示文摘 | O’HARE T EIDE CA DEININGER MW | 2008 | J Natl Cancer Inst2008，100，13： | 1 |
| 19 | Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins 显示文摘 | DAVARE MA SABOROWSKI A EIDE CA | 2013 | Proc Natl Acad Sci USA2013，110，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员